NEW YORK, NY / ACCESSWIRE / December 7, 2015 / UltimateStockAlerts.com is an exclusively NASDAQ & NYSE stock alert service focused on day and swing trading. Today we’d like to take a look at four companies which have attracted a lot of investor attention recently. In our opinion, all four could provide investors with increased upside and downside opportunities.
CTI BioPharma Corp. (CTIC) had a torrid time in its last session. By the end of Friday’s trading the company which develops drugs for the treatment of cancer was down 10.26%. It had declined as much as 32% after the announcement that it was pricing $55 million worth of convertible preferred stock. Investors didn’t like the move, largely because convertible stock offerings incite fears of dilution. There was positive news on the trial front for CTIC, however. The company announced the results of a new analysis of the pivotal Phase 3 trial, PERSIST-1. Results showed consistent rates of spleen volume reduction and control of disease-related symptoms. While RSI for CTIC suggests entering an area of longer-term undervaluation, more downside may be at hand in the near term, until Friday’s extreme downside move is retested for possible support. We are monitoring developments surrounding CTIC and will update our newsletter readers when opportunities for gains arise.
Live Ventures Incorporated. (LIVE) is currently trading at 2.34 following a 64.79% rally on Friday. Investors have been very excited about LIVE ever since it announced plans to sell all 7 properties owned and managed by its wholly owned subsidiary, Marquis Industries. Interestingly, LIVE closed Friday’s session at its 200 DMA of 2.34, which may serve as an area of significant resistance that would need to be tested for further upside to occure. Likewise, RSI has reached 75, a level suggesting that any upside that exists may be limited in strength. Tracking back to the beginning of its uptrend in August, LIVE has climbed a total of 212%. The company plans to release a special fourth quarter release on December 10. We’ll monitor LIVE and update our readers as soon as we see any potential for gains.
Our newsletter subscribers have realized average gains of 267% in 2015.
STOCKS TO BUY: Breaking NASDAQ & NYSE Stocks Below $10 With Upside Potential.
Orexigen Therapeutics, Inc. (OREX) faces an uphill task as it looks to regain some confidence from investors. The maker of pharmaceutical products in the United States was just in January one of Well Fargo’s top biotech picks for 2015. Lackluster sales forced Wells Fargo to issue a downgrade for the stock that led to the 8.60% tumble in Friday’s session. OREX is approaching an area of previous support, that when tested could provide for a near term bounce opportunity. OREX is trading below its 50 DMA of 2.57 by 21%. As with all the companies featured here, OREX will continue to be monitored. If any gain opportunity arises, we’ll issue updates to our newsletter readers accordingly.